Compounds > l 696040
Page last updated: 2024-12-07

l 696040

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

L 696040: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID131887
CHEMBL ID415320
SCHEMBL ID9281450
MeSH IDM0191631

Synonyms (17)

Synonym
chembl415320 ,
3-{[1,3-benzoxazol-2-yl)-methyl]amino}-5-ethyl-6-methylpyridin-2(1h)-one
bdbm1283
3-[(1,3-benzoxazol-2-ylmethyl)amino]-5-ethyl-6-methyl-1,2-dihydropyridin-2-one
l 696040
2(1h)-pyridinone, 3-((2-benzoxazolylmethyl)amino)-5-ethyl-6-methyl-
135525-70-1
3-(1,3-benzoxazol-2-ylmethylamino)-5-ethyl-6-methyl-1h-pyridin-2-one
2(1h)-pyridinone, 3-[(2-benzoxazolylmethyl)amino]-5-ethyl-6-methyl-
3-[(2-benzoxazolylmethyl)amino]-5-ethyl-6-methylpyridin-2(1h)-one
l-696,040
SCHEMBL9281450
AKOS030539284
3-{[(1,3-benzoxazol-2-yl)methyl]amino}-5-ethyl-6-methylpyridin-2-ol
DTXSID00929040
3-((benzo[d]oxazol-2-ylmethyl)amino)-5-ethyl-6-methylpyridin-2(1h)-one
bdbm50594991
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gag-Pol polyproteinHIV-1 M:B_HXB2RIC50 (µMol)0.21000.00060.91418.3200AID1795306; AID1795378
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC50 (µMol)0.16780.00011.076810.0000AID1872683; AID197804; AID198241; AID198397; AID199074
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1IC95 (µMol)0.80000.10000.45000.8000AID106773
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
viral life cycleGag-Pol polyproteinHIV-1 M:B_HXB2R
establishment of integrated proviral latencyGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
peptidase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
integrase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID198397Tested for inhibition against HIV-1 RT (used (poly)rC-(oligo)dG as the template)1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors. 4. 3-[2-(Benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2(1H)-one and analogues.
AID1872683Inhibition of HIV-1 reverse transcriptase using rC.dG as primer/template2022European journal of medicinal chemistry, Mar-15, Volume: 232A score years' update in the synthesis and biological evaluation of medicinally important 2-pyridones.
AID197804In vitro HIV-1 RT inhibitory activity using rC.dG as template-primer1992Journal of medicinal chemistry, Oct-16, Volume: 35, Issue:21
Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors. 2. Analogues of 3-aminopyridin-2(1H)-one.
AID27059Half life was determined1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors. 4. 3-[2-(Benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2(1H)-one and analogues.
AID106777Compound was evaluated for antiviral activity in MT-4 cells. Cell culture inhibitor concentration (CIC95) is defined as concentration which inhibited >95% the spread of HIV-1 IIIb infection in susceptible cell culture1992Journal of medicinal chemistry, Oct-16, Volume: 35, Issue:21
Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors. 2. Analogues of 3-aminopyridin-2(1H)-one.
AID198241Inhibitory activity against HIV-1 reverse transcriptase (RT)1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
2-Pyridinone derivatives: a new class of nonnucleoside, HIV-1-specific reverse transcriptase inhibitors.
AID106773Cell culture inhibitor concentration required to inhibit the spread of HIV-1 strain III B infection in MT-4 human T-lymphoid cells1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors. 4. 3-[2-(Benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2(1H)-one and analogues.
AID199074Inhibition of HIV-1 reverse transcriptase (HIV-1 RT)1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Principal components describing biological activities and molecular diversity of heterocyclic aromatic ring fragments.
AID493017Wombat Data for BeliefDocking1993Journal of medicinal chemistry, Apr-16, Volume: 36, Issue:8
Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors. 4. 3-[2-(Benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2(1H)-one and analogues.
AID1795378HIV-1 RT Assay from Article 10.1021/jm00113a036: \\2-Pyridinone derivatives: a new class of nonnucleoside, HIV-1-specific reverse transcriptase inhibitors.\\1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
2-Pyridinone derivatives: a new class of nonnucleoside, HIV-1-specific reverse transcriptase inhibitors.
AID1795306HIV-1 RT Assay from Article 10.1021/jm00099a007: \\Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors. 2. Analogues of 3-aminopyridin-2(1H)-one.\\1992Journal of medicinal chemistry, Oct-16, Volume: 35, Issue:21
Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors. 2. Analogues of 3-aminopyridin-2(1H)-one.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (83.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.50 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
nevirapine
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.		2.3820cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
benzoxazoles
1,3-benzoxazole : A benzoxazole in which the benzene ring is fused to a 1,3-oxazole ring across positions 4 and 5.. benzoxazole : Compounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton.		1.97101,3-benzoxazoles;
mancude organic heterobicyclic parent
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		1.9810azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
l 697639
L 697639: structure given in first source		2.6730
l 693593
L 693593: structure given in first source		4.0140
l-697661
L-697661: HIV-1 reverse transcriptase inhibitor		2.6730
r 82150
R 82150: structure given in first source; inhibits HIV-1 replication		2.3820
oligonucleotides
[no description available]		1.9710
ConditionIndicatedRelationship StrengthStudiesTrials